ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
Abstract
The identification of unique cell-surface proteins expressed on tumor cells, yet not expressed on normal tissues, has been challenging for pediatric malignancies. The cell sur-face tyrosine kinase ALK (CD246, anaplastic lymphoma kinase) is a promising target for neuroblastoma in that it is expressed in either native, mutated, or over-expressed forms on the plasma membrane surface
Fichier principal
2051-1426-1-S1-P27.pdf (173.83 Ko)
Télécharger le fichier
2051-1426-1-S1-P27.xml (3.92 Ko)
Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other